Professor Schett is Head of Department of Internal Medicine 3-Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. His interests include basic, translational and clinical research on molecular and cellular pathogenesis of rheumatic and autoimmune diseases. In 2008, he initiated in collaboration with colleagues the priority program IMMUNOBONE, funded by the German Research Foundation (DFG), which aims to elucidate the interactions between the skeletal and the immune systems.
Since 2015, Prof. Schett has led the DFG CRC1181 “Checkpoints for Resolution of Inflammation” in Erlangen. Additionally, he is spokesperson of the project METARTHROS, which investigates the impact of the metabolism on arthritis. Recently, he received funding for the ERC-Synergy grant “4D+ nanoSCOPE Advancing osteoporosis medicine by observing bone microstructure and remodelling using a four-dimensional nanoscope” of which he is spokesperson.
Professor Schett‘s scientific work has been honoured with several awards, including the Carol-Nachmann Prize from Wiesbaden. He has published over 650 peer-reviewed papers.
Professor Matthew Brown is an internationally renowned clinician-scientist, recently appointed Director of the National Institute for Health Research (NIHR) Guy’s and St Thomas’ Biomedical Research Centre (BRC) and Professor of Medicine within the Faculty of Life Sciences and Medicine. His previous role was as Director of Genomics and Distinguished Professor, at the Queensland University of Technology.
Professor Brown trained as a clinician-scientist and a rheumatologist, including a period of post-graduate study at the University of Oxford. He has made contributions to the development of gene-mapping approaches in human diseases and genome-wide association study methodology, leading to the discovery of thousands of genetic variants, with a particular interest in ankylosing spondylitis, rheumatoid arthritis and osteoporosis. In the genetics of rare human diseases, he has identified genes responsible for monogenic forms of arthritis, ectopic bone development, and skeletal dysplasias. He has also led efforts in Australia to translate research sequencing capability into precision medicine programs for cancer patients.
Mr Chris Martey is an Extended Scope Physiotherapist and injection therapist working as a Musculoskeletal First Contact Practitioner in primary care. Chris currently works within GP surgeries and community hospitals across Bath and North East Somerset and has a specialist interest in Rheumatic and Musculoskeletal Diseases.
Chris completed a Sport and Exercise Science BSc (Hons) degree at Leeds Beckett University before undertaking his Masters Physiotherapy degree at the University of East Anglia, Norwich. He spent part of his early career working at the Royal National Hospital for Rheumatic Diseases, Bath, where he has kept close research links. Chris remains involved in Rheumatology research and is part of a Physiotherapy in Axial Spondyloarthritis (PaxSpA) research group based in Bath. His early academic activity is focused on physical activity and exercise interventions within SpA and SpA subtypes.
Chris has close links with the UK National Axial Spondyloarthritis Society (NASS) and the Bath Institute for Rheumatic Diseases (BIRD)and has spoken at patient and public engagement events for both charities.